Genomas® is a biomedical company bringing DNA-Guided medicine to clinical practice with products for personalized prescription of drugs used in the treatment of mental illness, diabetes, and cardiovascular disease (CVD). Our products eliminate trial-and-error prescription with DNA-Guided medicine and enable physicians to treat with unprecedented precision, avoiding significant drug side effects, improving efficacy and enhancing patient compliance. Core applications are drug treatments of mood and thought disorders in mental illness and of cardiometabolic risk in diabetes and CVD. The products are developed in partnership with 3 leading Connecticut medical institutions, Hartford Hospital, The Institute of Living and Hospital of Central CT and with the University of Puerto Rico Medical Sciences.
A PhyzioType System consists of 3 components: an array of inherited, stable DNA polymorphisms from various genes to establish a patient’s combinatorial genotype, bioclinical algorithms for predicting the patient’s drug response, and a portal for doctors to select the best drug for the patient. PhyzioType Systems can be employed prognostically before prescribing drugs or diagnostically to manage patients evidencing drug intolerance or resistance. Clinical genotyping is provided through the Genomas Laboratory of Personalized Health (LPH, www.genomas.com/LPH), a high-complexity molecular diagnostic center, certified by the Centers for Medicare and Medicaid and licensed by the CT Department of Public Health.
The Genomas product portfolio encompasses 4 PhyzioType Systems:
HILOmet PhyzioType™ System on the market for the individualized management of the most frequently prescribed drugs in medicine. The HILOmet PhyzioType and its interactive user inerface, Personalized Health Portal, provide pharmacogenetic decision support for 250 medications: 130 neuro-psychiatric drugs (antidepressants, analgesics, neuroleptics, anticonvulsants, anxiolytics, stimulants, sedatives) and 120 cardio-metabolic drugs (to treat hypertension, diabetes, angina, thrombosis, gastric reflux, erectile dysfunction, asthma).
PIMS PhyzioType™ System is in development for the diagnosis and prevention of Psychotropic-Induced Metabolic Symptoms associated with atypical antipsychotic (AAP) drugs. The product predicts the risk of drug-induced pre-diabetic and metabolic symptoms resulting from AAPs and provides guidance on drug selection. Up to 30% of patients on AAPs are at risk. The system gives the physician the patient’s risk profile for the major AAPs, olanzapine, quetiapine, and risperidone.
SINM PhyzioType™ System is in development for the management of Statin Induction + Neuro-Myopathy required during aggressive lipid lowering in diabetes and CVD. The SINM PhyzioType System provides the physician with drug-specific efficacy prediction for LDL lowering, HDL raising, and a risk profile for neuromuscular side effects of atorvastatin, rosuvastatin, and simvastatin.
GLIM PhyzioType™ System is in development for prescribing Glucose + Insulin Modulators required during aggressive glucose lowering in diabetes and CVD. The GLIM PhyzioType System provides efficacy and safety predictions for thiazolidinedione (TZD) drugs pioglitazone and rosiglitazone and incretin drugs exenatide and sitagliptin. TZD and incretin therapies are associated, respectively, with cardiovascular and gastrointestinal side effects.
Genomas Inc. was founded in 2004 by Gualberto Ruaño, M.D., Ph. D., its President and CEO. Dr. Ruaño has 20 years of experience in biotechnology, having founded BIOS Laboratories in 1992 and Genaissance Pharmaceuticals in 1997, which he led as CEO to several pharmaceutical partnerships and to an IPO in NASDAQ. With M.D. and Ph.D. degrees from Yale, and a baccalaureate from Johns Hopkins, Dr. Ruaño is one of the leading business and medical experts in personalized medicine and translational genomics worldwide. Genomas is strategically located on the campus of Hartford Hospital, one of New England’s largest and most respected medical centers.